- Home
- CATX
as 03-28-2025 4:00pm EST
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 183.2M | IPO Year: | N/A |
| Target Price: | $15.30 | AVG Volume (30 days): | 531.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $19.10 | Next Earning Date: | 03-26-2025 |
| Revenue: | $1,454,000 | Revenue Growth: | 1.40% |
| Revenue Growth (this year): | -48.34% | Revenue Growth (next year): | 1.15% |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk
GlobeNewswire
3 days ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
MT Newswires
12 days ago
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy
![Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](https://cdn.finquota.com/news/713137ce-a5c2-424a-9526-55363311475a.jpg)
GlobeNewswire
12 days ago
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
MT Newswires
16 days ago
HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target
MT Newswires
19 days ago
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target
Zacks Small Cap Research
a month ago
LNTH: 2025 Guidance Provided
GlobeNewswire
a month ago
Perspective Therapeutics to Present at Upcoming March Investor Conferences
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.